Phase 1 × Hodgkin Disease × Gastrointestinal × Clear all
NCT05400122 2025-11-12

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Case Comprehensive Cancer Center

Phase 1 Suspended
12 enrolled
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
NCT02890758 2023-02-21

Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803

Case Comprehensive Cancer Center

Phase 1 Completed
14 enrolled
NCT00036790 2019-12-17

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

University of Wisconsin, Madison

Phase 1 Completed
NCT00581815 2015-12-28

Spectroscopy With Surface Coils and Decoupling

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
582 enrolled
NCT00413075 2015-07-08

Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma

Valerio Therapeutics

Phase 1 Completed
121 enrolled
NCT00608361 2015-07-02

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1 Completed
80 enrolled
NCT01158274 2014-11-07

RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
NCT00073944 2013-05-30

BCX-1777 in Treating Patients With Refractory Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT00019513 2012-03-23

Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
108 enrolled